Resources from the same session
1913O - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Presenter: Mimi Hu
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
1156O - Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)
Presenter: Jianming Xu
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
1160O - An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis
Presenter: Guillaume Nicolas
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
1157O - A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
Presenter: Jaume Capdevila
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
Q&A and live discussion
Presenter: Eva Segelov
Session: Proffered Paper - NETs
Resources:
Webcast
Invited Discussant 1157O and 1913O
Presenter: Nicola Fazio
Session: Proffered Paper - NETs
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Eva Segelov
Session: Proffered Paper - NETs
Resources:
Webcast